• Filana Therapeutics cleared to restart simufilam development in TSC-related epilepsy after the FDA lifted a clinical hold on its IND.
• Patient screening for a Phase 2a proof-of-concept trial is expected to start in Q1 2027; no study results have been presented yet.
• The 16-week randomized, double-blind study targets 40 patients ages 12 to 55 across 13 U.S. sites, with an optional 48-week extension.
• Readout is expected to guide next-stage development decisions, including whether to expand into younger patient groups.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Filana Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006161), on September 22, 2026, and is solely responsible for the information contained therein.